share_log

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Newman James W. Jr.

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities

Adial Pharmaceuticals | 4：持股變動聲明
美股SEC公告 ·  03/27 18:25
Moomoo AI 已提取核心訊息
James W. Newman Jr., a reporting person for Adial Pharmaceuticals, Inc. (ADIL), has engaged in a transaction involving the company's stock. The action took place on March 25, 2024. However, the announcement did not disclose the nature of the transaction, including the action type, status, number of shares involved, transaction price, or the resulting number of shares held after the action. Without these details, the total value of the shares cannot be determined. The relationship of Newman to the issuer was also not specified in the provided information.
James W. Newman Jr., a reporting person for Adial Pharmaceuticals, Inc. (ADIL), has engaged in a transaction involving the company's stock. The action took place on March 25, 2024. However, the announcement did not disclose the nature of the transaction, including the action type, status, number of shares involved, transaction price, or the resulting number of shares held after the action. Without these details, the total value of the shares cannot be determined. The relationship of Newman to the issuer was also not specified in the provided information.
阿迪爾製藥公司（ADIL）的舉報人小詹姆斯·紐曼參與了一項涉及該公司股票的交易。該行動於 2024 年 3 月 25 日進行。但是，該公告沒有透露交易的性質，包括行動類型、狀態、所涉股票數量、交易價格或行動後由此產生的持股數量。沒有這些細節，就無法確定股票的總價值。所提供的信息中也沒有具體說明紐曼與發行人的關係。
阿迪爾製藥公司（ADIL）的舉報人小詹姆斯·紐曼參與了一項涉及該公司股票的交易。該行動於 2024 年 3 月 25 日進行。但是，該公告沒有透露交易的性質，包括行動類型、狀態、所涉股票數量、交易價格或行動後由此產生的持股數量。沒有這些細節，就無法確定股票的總價值。所提供的信息中也沒有具體說明紐曼與發行人的關係。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息